Ospina Fabio E, Agualimpia Andrés, Bonilla-Abadía Fabio, Cañas Carlos A, Tobón Gabriel J
Instituto de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia ; Fundación Valle del Lili, Cra 98, No. 18-49, Cali, Colombia.
Fundación Valle del Lili, Cra 98, No. 18-49, Cali, Colombia.
Case Rep Rheumatol. 2014;2014:835050. doi: 10.1155/2014/835050. Epub 2014 Sep 17.
Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovial membrane inflammation and joint cartilage destruction. Abatacept is a biologic agent that blocks the costimulation signals, preventing antigen presentation and proliferation of T lymphocytes. It is approved for the treatment of patients with RA. Pneumocystis jirovecii pneumonia (PJP) is an infectious disease complicating several immunosuppressive drugs. PJP associated with abatacept has not been reported yet in the medical literature. Various factors, such as the mechanism of action of abatacept, may contribute to predisposing to Pneumocystis jirovecii infection. In this paper, we report a patient with RA who developed PJP under abatacept treatment.
类风湿性关节炎（RA）是一种自身免疫性疾病，其特征为滑膜炎症和关节软骨破坏。阿巴西普是一种生物制剂，可阻断共刺激信号，防止抗原呈递和T淋巴细胞增殖。它被批准用于治疗RA患者。耶氏肺孢子菌肺炎（PJP）是一种使多种免疫抑制药物产生并发症的传染病。医学文献中尚未报道过与阿巴西普相关的PJP。阿巴西普的作用机制等多种因素可能易导致耶氏肺孢子菌感染。在本文中，我们报告了1例在接受阿巴西普治疗期间发生PJP的RA患者。
